Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Lifecore Biomedical Reports Financial Results for the Second Quarter Ended June 30, 2026, and Provides Corporate Update
Lifecore Biomedical reported Q2 revenue of $34.2 million, down 6.2% year-over-year, with a net loss of $6.2 million or $0.19 per share.
Despite the revenue decline, the company reaffirmed its full-year 2026 guidance for revenue of $120-$125 million and Adjusted EBITDA of $20.5-$25 million.
Management highlighted the addition of 13 new programs over the last 12 months, including eight late-stage programs, and noted ongoing cost reduction initiatives aimed at achieving long-term profitability targets.